Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Koch, Alexander ^a   Voigt, Sebastian ^a   Kruschinski, Carsten ^b   Sanson, Edouard ^a   Dückers, Hanna ^a   Horn, Andreas ^a   Yagmur, Eray ^c   Zimmermann, Henning ^a   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Medical Laboratory Dr Stein   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANTITHROMBIN III; BILIRUBIN; C REACTIVE PROTEIN; CHOLINESTERASE; CREATININE; CYSTATIN C; GAMMA GLUTAMYLTRANSFERASE; PROCALCITONIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR; UREA; UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; AGED; ALKALOSIS; APACHE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LENGTH OF STAY; LIVER DYSFUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; MORTALITY; OVERALL SURVIVAL; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CRITICAL ILLNESS; FOLLOW UP; MIDDLE AGED; PREDICTIVE VALUE; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CRITICAL ILLNESS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEPSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951557734     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10037     Document Type: Article

References (34)

1. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943. 10.1038/nrm977, 12461559.
2. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 2007, 177:927-939. 10.1083/jcb.200612058, 2064291, 17548516.
3. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008, 87:617-629. 10.1016/j.ejcb.2008.02.003, 18353489.
4. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS 1999, 107:120-127. 10.1111/j.1699-0463.1999.tb01534.x, 10190288.
5. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27:157-172.
6. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brunner N, Blasi F. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999, 79:717-722.
7. De Witte H, Sweep F, Brunner N, Heuvel J, Beex L, Grebenschikov N, Benraad T. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998, 77:236-242. 10.1002/(SICI)1097-0215(19980717)77:2<236::AID-IJC12>3.0.CO;2-9, 9650559.
8. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997, 43:1868-1876.
9. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36:14-19. 10.1080/00365540310017366, 15000553.
10. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6:686-692.
11. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008, 27:375-383. 10.1007/s10096-007-0447-5, 18197443.
12. Gressner OA, Koch A, Sanson E, Trautwein C, Tacke F. High C5a levels are associated with increased mortality in sepsis patients--no enhancing effect by actin-free Gc-globulin. Clin Biochem 2008, 41:974-980. 10.1016/j.clinbiochem.2008.05.005, 18538666.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
14. Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009, 13:R95. 10.1186/cc7925, 2717467, 19545363.
15. Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Duckers H, Trautwein C, Tacke F. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care 2010, 14:R179. 10.1186/cc9285, 2934396, 20932285.
16. Koch A, Sanson E, Helm A, Voigt S, Trautwein C, Tacke F. Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis. Crit Care 2010, 14:R94. 10.1186/cc9029, 2911731, 20500817.
17. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11:R38. 10.1186/cc5723, 2206456, 17362525.
18. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001, 16:233-239.
19. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52:1284-1293. 10.1373/clinchem.2006.067595, 16690735.
20. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004, 35:337-342. 10.1097/00126334-200404010-00002, 15097149.
21. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000, 60:7126-7132.
22. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005, 191:1331-1341. 10.1086/428854, 15776381.
23. Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem 2009, 321:111-122. 10.1007/s11010-008-9925-z, 18830568.
24. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96:4091-4095.
25. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:23-31. 10.1097/01.qai.0000157950.02076.a6, 15851910.
26. Connolly BM, Choi EY, Gardsvoll H, Bey AL, Currie BM, Chavakis T, Liu S, Molinolo A, Ploug M, Leppla SH, Bugge TH. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 2010, 116:1593-1603. 10.1182/blood-2010-03-276642, 20466854.
27. Shapiro NI, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak S, Ngo L, Aird WC. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010, 14:R182. 10.1186/cc9290, 20942957.
28. Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 2009, 14:986-994. 10.1111/j.1365-3156.2009.02328.x, 19725925.
29. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004, 10:409-415. 10.1111/j.1469-0691.2004.00850.x, 15113317.
30. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22:205-222. 10.1023/A:1023099415940, 12784997.
31. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999, 58:488-492. 10.1136/ard.58.8.488, 1752924, 10419867.
32. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Moller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010, 268:296-308. 10.1111/j.1365-2796.2010.02252.x, 20561148.
33. Rabna P, Andersen A, Wejse C, Oliveira I, Francisco Gomes V, Bonde Haaland M, Aaby P, Eugen-Olsen J. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation 2010, 33:374-380. 10.1007/s10753-010-9195-2, 20229356.
34. Schneider UV, Nielsen RL, Pedersen C, Eugen-Olsen J. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms. BMC Infect Dis 2007, 7:134. 10.1186/1471-2334-7-134, 2216028, 18021410.